Report from the 1st Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group
Language English Country England, Great Britain Media electronic
Document type Congress
PubMed
26892706
PubMed Central
PMC4758171
DOI
10.1186/s12933-016-0357-x
PII: 10.1186/s12933-016-0357-x
Knihovny.cz E-resources
- MeSH
- Diabetes Mellitus diagnosis drug therapy epidemiology MeSH
- Hypoglycemic Agents therapeutic use MeSH
- Cardiovascular Diseases diagnosis epidemiology prevention & control MeSH
- Clinical Trials as Topic methods MeSH
- Humans MeSH
- Risk Factors MeSH
- Research Design MeSH
- Check Tag
- Humans MeSH
- Publication type
- Congress MeSH
- Names of Substances
- Hypoglycemic Agents MeSH
The 1st Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group was held during the annual meeting on 30 October 2015 in Munich. This summit was organized in light of recently published and numerous ongoing CVOTs on diabetes, which have emerged in response to the FDA and the EMA Guidelines. The CVOT Summit stands as a novel conference setup, with the aim of serving as a reference meeting for all topics related to CVOTs in diabetes. Members of the steering committee of the D&CVD EASD Study Group constitute the backbone of the summit. It included presentations of key results on DPP-4 inhibitors, GLP-1-Analogues, SGLT-2 inhibitors, acarbose and insulins. Diabetologists' and cardiologists' perspective on the potential need of new study designs were also highlighted. Furthermore, panel discussions on the design of CVOTs on diabetes were included in the program. The D&CVD EASD Study Group will continue its activity. In-depth discussions and presentations of new CVOTs like LEADER, will be resumed at the 2nd CVOT on diabetes of the D&CVD EASD Study Group, which will be held from 20-22 October 2016 in Munich ( http://www.dcvd.org).
See more in PubMed
Center for Drug Evaluation and Research. Guidance for industry diabetes mellitus: evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes, 2008. Available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf. Accessed 12 Jan 2016.
European Medicines Agency. Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129256.pdf. Accessed 12 Jan 2016.
CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes
CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes
